Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib + Abiraterone in mCRPC (Study 8)
NCT01972217Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2014
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 11
01
Overview
A Phase 2 trial of olaparib in metastatic castration-resistant prostate cancer (mCRPC), sponsored by AstraZeneca. Started Apr 2014; status: completed.
02
Drugs
olaparib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT01972217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01972217.